Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 6301–6350 of 35164
On October 30, 2024, Ulf Wiinberg resigned as a director at Agenus Inc. (the “Company”), effective as of 5:00 p.m. Eastern Time on November 5, 2024.
On October 30, 2024, Wetteny Joseph, a member of the Board of Directors (the “Board”) of Ashland Inc. (the “Company”), notified the Company of his decision to not stand for reelection to the Board at the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”).
On November 1, 2024, the Board of Directors of the Company, appointed Felicia Williams to serve as a member of the Board, the Company’s Audit and Finance Committee (the “Audit Committee”) and the Company’s Nominating and Corporate Governance Committee (the “NCG Committee”).
On November 1, 2024, the Board of Directors of Utah Medical Products, Inc. (UTMD) voted to increase the size of the Board of Directors from five to six members and to appoint Carrie Leigh to fill the vacancy created by the increase in the number of directors.
Michael (Mike) S. Curless, Samantha (Sam) J. Marnick, Carl J. (Rick) Rickertsen, Thomas (Tom) E. Salmon and Mary Dean Hall, Berry’s designees pursuant to its rights under the RMT Agreement, and Curtis L. Begle as the CEO designee, in accordance with the RMT Agreement, were elected to the Board.
Michael (Mike) S. Curless, Samantha (Sam) J. Marnick, Carl J. (Rick) Rickertsen, Thomas (Tom) E. Salmon and Mary Dean Hall, Berry’s designees pursuant to its rights under the RMT Agreement, and Curtis L. Begle as the CEO designee, in accordance with the RMT Agreement, were elected to the Board.
Michael (Mike) S. Curless, Samantha (Sam) J. Marnick, Carl J. (Rick) Rickertsen, Thomas (Tom) E. Salmon and Mary Dean Hall, Berry’s designees pursuant to its rights under the RMT Agreement, and Curtis L. Begle as the CEO designee, in accordance with the RMT Agreement, were elected to the Board.
Michael (Mike) S. Curless, Samantha (Sam) J. Marnick, Carl J. (Rick) Rickertsen, Thomas (Tom) E. Salmon and Mary Dean Hall, Berry’s designees pursuant to its rights under the RMT Agreement, and Curtis L. Begle as the CEO designee, in accordance with the RMT Agreement, were elected to the Board.
Michael (Mike) S. Curless, Samantha (Sam) J. Marnick, Carl J. (Rick) Rickertsen, Thomas (Tom) E. Salmon and Mary Dean Hall, Berry’s designees pursuant to its rights under the RMT Agreement, and Curtis L. Begle as the CEO designee, in accordance with the RMT Agreement, were elected to the Board.
Michael (Mike) S. Curless, Samantha (Sam) J. Marnick, Carl J. (Rick) Rickertsen, Thomas (Tom) E. Salmon and Mary Dean Hall, Berry’s designees pursuant to its rights under the RMT Agreement, and Curtis L. Begle as the CEO designee, in accordance with the RMT Agreement, were elected to the Board.
elected Allison K. Aden as a director, effective November 5, 2024
Mr. Read was also appointed, as of the Effective Date, to serve as a member of the Board as a Class III director for a term expiring at the Company’s 2027 Annual Meeting of Stockholders.
On November 4, 2024, the Board of Directors (the “Board”) of MKS Instruments, Inc. (the “Company”) appointed Wissam Jabre as a Class III Director, effective November 4, 2024, to serve until the 2026 Annual Meeting of Shareholders.
Mr. Yee will fill an upcoming vacancy resulting from the December 11, 2024 retirement of long-time Director Geoffrey L. Stack.
Ms. Gammon, Mr. McCall and Mr. Speron will join the Board effective immediately.
Ms. Gammon, Mr. McCall and Mr. Speron will join the Board effective immediately.
Mr. Yee will join the Board effective December 11, 2024.
Ms. Gammon, Mr. McCall and Mr. Speron will join the Board effective immediately.
On October 30, 2024, the Board of Directors of Unitil Corporation (the “Company”) elected Jane Lewis-Raymond as a Director, effective immediately.
the Board also appointed Mr. Brown as a director of the Board effective the Effective Date
the vacancy being created by William J. Fehrman’s resignation
Karin Rådström and Kristin Slanina resigned as members of Ouster, Inc.’s (the “Company”) Board of Directors (the “Board”), effective November 4, 2024.
On November 4, 2024, Christina Correia and Stephen Skaggs were elected to the Board, effective as of November 4, 2024.
Karin Rådström and Kristin Slanina resigned as members of Ouster, Inc.’s (the “Company”) Board of Directors (the “Board”), effective November 4, 2024.
On November 4, 2024, Christina Correia and Stephen Skaggs were elected to the Board, effective as of November 4, 2024.
On November 1, 2024, Dr. Hideki Garren provided Coya Therapeutics, Inc. (the “Company”) with notice of his resignation from the Board of Directors, effective immediately.
On November 1, 2024, in connection with the IPO, Nazim Cetin, Joseph Samuels, Kathy Savitt, Antoine Theysset and Pierre Weinstein (collectively with Andrew Gundlach, the “ Directors ”) were appointed to the board of directors of the Company (the “ Board ”).
On November 1, 2024, in connection with the IPO, Nazim Cetin, Joseph Samuels, Kathy Savitt, Antoine Theysset and Pierre Weinstein (collectively with Andrew Gundlach, the “ Directors ”) were appointed to the board of directors of the Company (the “ Board ”).
On November 1, 2024, in connection with the IPO, Nazim Cetin, Joseph Samuels, Kathy Savitt, Antoine Theysset and Pierre Weinstein (collectively with Andrew Gundlach, the “ Directors ”) were appointed to the board of directors of the Company (the “ Board ”).
On November 1, 2024, in connection with the IPO, Nazim Cetin, Joseph Samuels, Kathy Savitt, Antoine Theysset and Pierre Weinstein (collectively with Andrew Gundlach, the “ Directors ”) were appointed to the board of directors of the Company (the “ Board ”).
On November 1, 2024, in connection with the IPO, Nazim Cetin, Joseph Samuels, Kathy Savitt, Antoine Theysset and Pierre Weinstein (collectively with Andrew Gundlach, the “ Directors ”) were appointed to the board of directors of the Company (the “ Board ”).
I-Tseng Jenny Chan resigned as a member of the Board.
appointed Armon Vakili and Richard Drexler as members of the Board.
appointed Armon Vakili and Richard Drexler as members of the Board.
On November 1, 2024, June Almenoff, M.D., Ph.D., was appointed as a director of Actinium Pharmaceuticals, Inc. (the “Company”)
On November 5, 2024, the Federal Home Loan Bank of Topeka (FHLBank) declared elected the following individuals in FHLBank’s 2024 election of directors with terms commencing on January 1, 2025: • Milroy A. Alexander; Retired; Denver, Colorado (Public Interest Independent Director) • Kyle J. Heckman; Chairman; Flatirons Bank; Boulder, Colorado (Member Director) • Lynn Jenkins; Consultant; Eudora, Kansas (Independent Director) • Christopher D. Wente; President/CEO; Golden Belt Bank; Hays, Kansas (Member Director) Each director will serve a four-year term expiring December 31, 2028.
On November 5, 2024, the Federal Home Loan Bank of Topeka (FHLBank) declared elected the following individuals in FHLBank’s 2024 election of directors with terms commencing on January 1, 2025: • Milroy A. Alexander; Retired; Denver, Colorado (Public Interest Independent Director) • Kyle J. Heckman; Chairman; Flatirons Bank; Boulder, Colorado (Member Director) • Lynn Jenkins; Consultant; Eudora, Kansas (Independent Director) • Christopher D. Wente; President/CEO; Golden Belt Bank; Hays, Kansas (Member Director) Each director will serve a four-year term expiring December 31, 2028.
the Company increased the size of its Board of Directors (the “Board”) from eight to nine directors and appointed Robert L. Fleshman to serve as a director of the Company, effective November 8, 2024.
Nandita V. Berry and David F. Taylor will step down from the Board effective immediately.
announced the appointments of Kristian (“Krissy”) M. Gathright and Donald (“Don”) A. Miller, CFA, to the Board of Trustees, effective immediately.
announced the appointments of Kristian (“Krissy”) M. Gathright and Donald (“Don”) A. Miller, CFA, to the Board of Trustees, effective immediately.
Nandita V. Berry and David F. Taylor will step down from the Board effective immediately.
On November 4, 2024, the Board, upon the recommendation of the Nominating and Governance Committee of the Board (“Nominating Committee”), appointed Roberto Candelino as a Class I member of the Board to fill a vacancy.
On November 1, 2024, the Board of Directors (“the Board”) of Skkynet Cloud Systems, Inc. (“the Company”) appointed Mr. Xavier Mesrobian to serve as a director of the Company, effective immediately.
On October 31, 2024, Nicholas Cardosi was nominated and appointed as a Director of the Company.
On October 30, 2024, the Company accepted the resignations of Nicholas Fazio from his positions as Director and Chief Executive Officer of the Company
Trans-Lux Corporation announced the appointments of Messrs. Naibin (Robin) Tang and Xu He as Directors of the Company.
Trans-Lux Corporation announced the appointments of Messrs. Naibin (Robin) Tang and Xu He as Directors of the Company.
On November 2, 2024, the Board of Directors of T Stamp, Inc. (the “Company”) elected Andrew Scott Francis, the current Chief Technology Officer of the Company, to the Board of Directors, effective immediately, to fill a vacancy on the Board of Directors.
On November 1, 2024, Brian Krzanich resigned from the Board of Directors (the “Board”) of SES AI Corporation (“SES AI”) effective immediately.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.